Peek behind the paper: real-world data concerning the efficacy of osimertinib in a subset of NSCLC patients
In this feature, we peek behind the paper with contributing study author Filippo de Marinis (European Institute of Oncology, Milan, Italy): the ASTRIS study.
Please sign in or register for FREE
Sign in to The Evidence Base®
Did you know?
Your The Evidence Base™ account also gives you access to communities on regenerative medicine, real-world evidence and drug discovery. Find out more>>